Lupin Ltd - Company Profile
Powered by 
All the sales intelligence you need on Lupin Ltd in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Lupin Ltd fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Lupin Ltd.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Lupin Ltd (Lupin) is a pharmaceutical company primarily engaged in the development and distribution of a diverse range of healthcare products. The company's portfolio includes products with a focus on generics, branded generics, complex generics, APIs, biosimilars, and specialty medicines. Lupin's products cater to various therapeutic areas such as anti-tuberculosis, diabetes, cardiovascular, respiratory, women's health, and the central nervous system. The company offers generic medicines related to anti-TB, diabetes, cardiovascular, respiratory, and ophthalmic. Its biosimilar products include Filgrastim, Peg-Filgrastim, and Etanercept, and specialty products are focused on women's health and rare neurological disorders. Lupin also develops value-added generic pharmaceuticals based on its platform technologies. The company has its manufacturing units in India, the US, Mexico, and Brazil. Lupin is headquartered in Mumbai, Maharashtra, India.
Headquarters
India
Address
3rd Floor, Kalpataru Inspire, Off. Western Express, Mumbai, Maharashtra, 400055
Website
www.lupin.com
Telephone
91 226 6402323
No of Employees
19,021
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
LUPIN (NSE)
Revenue (2025)
$3.2B
23.1%
(2025 vs 2024)
EPS
XYZ
Net Income (2025)
XYZ
62.5%
(2025 vs 2024)
Market Cap*
$11.6B
Net Profit Margin (2025)
XYZ
32.0%
(2025 vs 2024)
* As of and is in US$
Lupin Ltd premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Anti-Tuberculosis | AKT |
| Diabetes Management | Akurit |
| Cardiac Care | Rcinex |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2026 | Regulatory Approval | In June, the company and Natco Pharma Limited received approval from the United States Food and Drug Administration for Natco's new drug application for Eribulin Mesylate Injection, 1 mg/2 mL (0.5 mg/mL) Single-Dose Vials. |
| 2026 | Regulatory Approval | In May, the company received approval from China's National Medical Products Administration for Oseltamivir Phosphate oral suspension. |
| 2026 | Others | In May, the company received the Establishment Inspection Report from the US Food and Drug Administration for its Ankleshwar facility in Gujarat, India. |
Competitor Comparison
| Key Parameters | Lupin Ltd | Sun Pharmaceutical Industries Ltd | Dr. Reddy's Laboratories Ltd | Cipla Ltd | Intas Pharmaceuticals Ltd |
|---|---|---|---|---|---|
| Headquarters | India | India | India | India | India |
| City | Mumbai | Mumbai | Hyderabad | Mumbai | Ahmedabad |
| State/Province | Maharashtra | Maharashtra | Telangana | Maharashtra | Gujarat |
| No. of Employees | 19,021 | 43,000 | 26,944 | 31,369 | - |
| Entity Type | Public | Public | Public | Public | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Ramesh Swaminathan | Chief Financial Officer; Director; Head - IT and API Plus SBU | Executive Board | 2020 | 59 |
| Rakesh Bhardwaj | Chief Information Officer | Senior Management | 2024 | - |
| Shahin Fesharaki | Chief Scientific Officer | Senior Management | 2022 | - |
| Mr. Christoph Funke | Chief Technical Operations Officer | Senior Management | 2024 | - |
| Ranjana Pathak | Chief Quality Officer | Senior Management | 2024 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer